Lung Cancer Vaccine:
The world’s first mRNA lung cancer vaccine, BNT116, has begun clinical trials across seven countries, including the UK, the US, Germany, Hungary, Poland, Spain, and Turkey.
- This vaccine targets non-small cell lung cancer (NSCLC), the most common form of the disease, by instructing the body to attack cancer cells and prevent their recurrence.
- The vaccine uses messenger RNA technology, similar to COVID-19 vaccines, to prompt the immune system to recognize and fight NSCLC cells.
